Tecentriq (Atezolizumab) vs Nerlynx (neratinib)
Tecentriq (Atezolizumab) vs Nerlynx (neratinib)
Tecentriq (atezolizumab) is an immune checkpoint inhibitor used primarily in the treatment of certain types of bladder, lung, breast, and other cancers by enhancing the body's immune response against cancer cells. Nerlynx (neratinib) is a tyrosine kinase inhibitor specifically indicated for the extended adjuvant treatment of HER2-positive breast cancer to reduce the risk of cancer recurrence following initial therapy. When deciding between Tecentriq and Nerlynx, it is crucial to consider the specific type and characteristics of the cancer being treated, as each medication is tailored for different targets and mechanisms of action within the cancer treatment paradigm.
Difference between Tecentriq and Nerlynx
Metric | Tecentriq (Atezolizumab) | Nerlynx (neratinib) |
---|---|---|
Generic name | Atezolizumab | Neratinib |
Indications | Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma | Early-stage breast cancer, metastatic breast cancer |
Mechanism of action | PD-L1 inhibitor, immune checkpoint inhibitor | Tyrosine kinase inhibitor |
Brand names | Tecentriq | Nerlynx |
Administrative route | Intravenous infusion | Oral |
Side effects | Fatigue, decreased appetite, nausea, urinary tract infection, fever, etc. | Diarrhea, nausea, abdominal pain, fatigue, vomiting, etc. |
Contraindications | None known | Liver impairment, severe kidney impairment, long QT syndrome |
Drug class | Monoclonal antibody, Immune checkpoint inhibitor | Tyrosine kinase inhibitor |
Manufacturer | Genentech (Roche) | Puma Biotechnology |
Efficacy
Tecentriq (Atezolizumab) in Breast Cancer
Tecentriq (atezolizumab) is an immune checkpoint inhibitor that has shown efficacy in the treatment of certain types of breast cancer. Specifically, it is indicated for use in combination with chemotherapy for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) that expresses PD-L1. The efficacy of Tecentriq in this setting was demonstrated in the IMpassion130 trial, a Phase III study that showed a significant improvement in progression-free survival (PFS) for patients with PD-L1-positive tumors compared to chemotherapy alone. The study also indicated a trend toward improved overall survival (OS), although at the time of analysis, the OS data was not yet mature.
Nerlynx (neratinib) in Breast Cancer
Nerlynx (neratinib) is a tyrosine kinase inhibitor that has been shown to be effective in the treatment of breast cancer, particularly in early-stage HER2-positive breast cancer. The ExteNET study, a large international, double-blind, placebo-controlled Phase III trial, demonstrated that neratinib significantly improved 2-year invasive disease-free survival (iDFS) when given after adjuvant trastuzumab therapy. Patients who received neratinib after standard adjuvant therapy had a 2-year iDFS rate of 94.2% compared to 91.9% for those who received placebo, indicating a relative reduction in the risk of invasive disease recurrence or death.
Combination Use and Further Considerations
While both Tecentriq and Nerlynx have shown efficacy in their respective indications for breast cancer, it is important to consider that the efficacy can vary based on the specific characteristics of the cancer, such as PD-L1 expression and HER2 status. Additionally, the combination of these drugs with other treatments, such as chemotherapy or other targeted therapies, can influence outcomes. It is essential for healthcare providers to evaluate the patient's overall health, cancer subtype, and previous treatments to determine the most appropriate therapeutic strategy.
Conclusion
In conclusion, Tecentriq and Nerlynx have both expanded the options available for treating different subtypes of breast cancer. Tecentriq's efficacy in PD-L1-positive TNBC and Nerlynx's efficacy in early-stage HER2-positive breast cancer represent significant advances in the personalized treatment of this disease. However, ongoing research and clinical trials continue to refine the use of these medications, including their efficacy and safety profiles, to optimize outcomes for patients with breast cancer.
Regulatory Agency Approvals
Tecentriq
Nerlynx
Access Tecentriq or Nerlynx today
If Tecentriq or Nerlynx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us